SUPERNUS PHARMACEUTICALS, INC. (SUPN): debt financing — Supernus to pay $33.4M CVR milestone payment after Milestone 1 achieved March 18

SUPERNUS PHARMACEUTICALS, INC.

Milestone 1 under July 2025 CVR Agreement achieved on March 18, 2026; triggers $0.50 per CVR payment.
Aggregate milestone payment ~$33.4 million, payable in cash within 20 business days of May 17, 2026 Notice Date.
Company will deposit funds with Rights Agent Equiniti Trust Company for distribution to CVR holders.
CVRs were issued as part of prior business combination; this payment reduces future contingent liability.

item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. incurred debt of approximately $33.4 million with Equiniti Trust Company, LLC.

Principal: approximately $33.4 million
Counterparty: Equiniti Trust Company, LLC
Event: incurrence

Exact text from the filing

On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026.

View on SEC.gov

Browse all debt financings →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.